<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527111</url>
  </required_header>
  <id_info>
    <org_study_id>05102</org_study_id>
    <secondary_id>CA225269</secondary_id>
    <nct_id>NCT00527111</nct_id>
  </id_info>
  <brief_title>Pre-op Rectal ChemoRad +/- Cetuximab</brief_title>
  <official_title>A Randomized Phase II Trial of Pre-operative Chemoradiotherapy With or Without Cetuximab (ERBITUX(R)) in Locally-advanced Adenocarcinoma of the Rectum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Oncology Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ImClone LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>US Oncology Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out what effects (good and bad) cetuximab has
      on rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rectal cancer remains a significant cause of morbidity and mortality in the United States.
      Standard treatment for patients with locally advanced rectal cancer generally includes
      combined chemotherapy and radiotherapy administered either before (neoadjuvant) or after
      (adjuvant) definitive surgical resection. Published data from Germany has suggested
      advantages to a neoadjuvant strategy. Currently, the standard concurrent chemoradiotherapy
      regimen in the United States is pelvic irradiation administered concurrently with
      5-fluorouracil (5-FU) given as a protracted venous infusion. However, local recurrence
      remains a problem. Recently completed randomized trials of chemoradiotherapy have
      demonstrated local recurrence rates between 8-17% even with currently accepted standard
      chemoradiotherapy and adequate surgical management.

      Several recent trials have explored the use of radiotherapy and cetuximab with good results.

      Because of the non-overlapping toxicity profiles and the potentially diverse and
      complimentary mechanisms of action, the combination of chemotherapy plus ERBITUX given
      concurrently with pelvic radiotherapy may improve on the outcomes seen with current standards
      for patients with locally advanced adenocarcinoma of the rectum.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.</measure>
    <time_frame>5 years</time_frame>
    <description>A pathologic complete response (pCR) is defined as no pathologic evidence of invasive disease at the primary site in the bowel wall or in examined mesorectal tissue and/or lymph nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine Objective Response Rate (ORR) Based on RECIST Local Recurrence-free Survival in These Patient Groups; Overall and Recurrence-free Survival in These Cohorts.</measure>
    <time_frame>5 years</time_frame>
    <description>Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5- Year Overall Survival (OS) Rate</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free Survival (RFS) Rate at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>RFS is measured from the date of randomization to the date of first documented disease recurrence or date of death, whichever comes first. If a patient neither recurrences nor dies, this patient will be censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KRAS Mutation Rate</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of Participants with KRAS mutation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoradiotherapy plus Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pelvic irradiation plus 5-fluorouracil plus cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pelvic irradiation plus 5-fluorouracil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Chemoradiotherapy plus Cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <arm_group_label>Chemoradiotherapy plus Cetuximab</arm_group_label>
    <arm_group_label>Chemoradiotherapy alone</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic irradiation</intervention_name>
    <arm_group_label>Chemoradiotherapy plus Cetuximab</arm_group_label>
    <arm_group_label>Chemoradiotherapy alone</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Note: Please see Section 8.1 for the necessary &quot;Prestudy Assessments&quot;.

        A patient will be eligible for inclusion in this study if s/he meets all of the following
        criteria:

          -  Has a histologically confirmed diagnosis of newly diagnosed adenocarcinoma of the
             rectum (tumor within 15 cm of the anal verge). Location of tumor (lower 1/3rd vs.
             middle or upper 1/3rd) and pre-treatment nodal status (N0 vs. N1 or N2) will be
             recorded in the eCRF. Patients with only non-measurable disease are eligible as long
             as they meet the other disease requirements in this criterion as well as all other
             eligibility criteria.

          -  Has tumor that is locally advanced (T3/T4 or lymph node positive) by preoperative
             assessment with CT or MRI imaging or transrectal ultrasonography.

          -  Has no evidence of distant metastases by radiographic staging

          -  Has an ECOG Performance Status (PS) 0-1

          -  Is greater than 18 years of age

          -  Has adequate marrow and organ system function as assessed by the following lab values:

        White blood cell (WBC) count See protocol for specific details Absolute neutrophil count
        (ANC) See protocol for specific details Hemoglobin See protocol for specific details Total
        bilirubin See protocol for specific details AST and ALT See protocol for specific details
        Serum creatinine See protocol for specific details Platelet count See protocol for specific
        details

          -  Sexually active women of childbearing potential must use an effective method of birth
             control during the course of the study, in a manner such that risk of failure is
             minimized.

        Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the
        importance of avoiding pregnancy during trial participation and the potential risk factors
        for an unintentional pregnancy. In addition, men enrolled on this study should understand
        the risks to any sexual partner of childbearing potential and should practice an effective
        method of birth control.

        All WOCBP MUST have a negative pregnancy test within 3 weeks prior to registration
        (confirmed within 7 days prior to first receiving investigational product). If the
        pregnancy test is positive, the patient must not receive investigational product and must
        not be enrolled in the study.

        In addition, all WOCBP should be instructed to contact the Investigator immediately if they
        suspect they might be pregnant (eg, missed or late menstrual period) at any time during
        study participation.

        The Investigator must immediately notify BMS in the event of a confirmed pregnancy in a
        patient participating in the study.

          -  Has signed a Patient Informed Consent Form

          -  Has signed a Patient Authorization Form

        Exclusion Criteria:

          -  A patient will be excluded from this study if s/he meets any of the following
             criteria:

          -  Has another disease similar to one being studied (ie, colon cancer)

          -  Has evidence of distant metastases by radiographic staging

          -  Has had prior treatment for the current disease

          -  Has had prior stem cell or bone marrow transplant or any organ transplant with the
             exception of corneal transplant or cadaver bone graft

          -  Has a history of hypersensitivity to any of study treatments

          -  Has had a prior severe infusion reaction to a monoclonal antibody

          -  Has received prior therapy, at any time, which specifically and directly targets the
             EGFR pathway

          -  Has a significant history of uncontrolled cardiac disease; ie, uncontrolled
             hypertension, unstable angina, recent myocardial infarction (within prior 6 months),
             uncontrolled congestive heart failure, or cardiomyopathy with decreased ejection
             fraction

          -  Has evidence of CNS involvement (CNS imaging is not required for study enrollment
             unless clinically suspected CNS disease is present.)

          -  Has a serious uncontrolled intercurrent medical or psychiatric illness, including
             serious infection or Gilbert's Syndrome

          -  Has a history of other malignancy within the last 5 years (except cured basal cell
             carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the
             diagnosis or assessment of any of the study drugs. Patients, who have received prior
             radiotherapy to any regional site other than the pelvis, as long as all other
             inclusion criteria are met, could be considered for enrollment after discussion with
             Dr. McCollum.

          -  Is a pregnant or nursing woman

          -  Is unable to comply with requirements of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D McCollum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Oncology Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Associates D.B.A. Hematology Oncology Physicians &amp; Extenders</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Internal Medicine Associates</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Specialties</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Florida, P.A.</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care &amp; Hematology Specialists of Chicagoland, PC</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>76227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers-Southwest</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Hematology Oncology PA</name>
      <address>
        <city>Westminster</city>
        <state>Maryland</state>
        <zip>21157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Cance Associates</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Oncology, Inc.</name>
      <address>
        <city>St. Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cance Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mamie McFaddin Ward Cancer Center</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center at Medical City</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Charlton Cancer Ctr.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Paso Cancer Treatment Ctr</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Vista Cancer Center</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longview Cance Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allison Cancer Center</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Odessa</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris Regional Cancer Center</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <zip>75460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOAST - Medical Dr.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cancer Center - Sherman</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cancer Center-Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cancer Care and Research</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texoma Cancer Center</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highline Medical Oncology</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest-South</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists-Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Mem Hosp/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Regional Cancer Center</name>
      <address>
        <city>Beckley</city>
        <state>West Virginia</state>
        <zip>25801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <results_first_submitted>January 12, 2016</results_first_submitted>
  <results_first_submitted_qc>September 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2016</results_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chemoradiotherapy Plus Cetuximab</title>
          <description>Pelvic irradiation plus 5-fluorouracil plus cetuximab
Cetuximab
5-fluorouracil
Pelvic irradiation</description>
        </group>
        <group group_id="P2">
          <title>Chemoradiotherapy Alone</title>
          <description>Pelvic irradiation plus 5-fluorouracil
5-fluorouracil
Pelvic irradiation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Request</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Request</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Chemoradiotherapy Plus Cetuximab</title>
          <description>Pelvic irradiation plus 5-fluorouracil plus cetuximab
Cetuximab
5-fluorouracil
Pelvic irradiation</description>
        </group>
        <group group_id="B2">
          <title>Chemoradiotherapy Alone</title>
          <description>Pelvic irradiation plus 5-fluorouracil
5-fluorouracil
Pelvic irradiation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.9" spread="11.0"/>
                    <measurement group_id="B2" value="61.4" spread="11.7"/>
                    <measurement group_id="B3" value="58.6" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.</title>
        <description>A pathologic complete response (pCR) is defined as no pathologic evidence of invasive disease at the primary site in the bowel wall or in examined mesorectal tissue and/or lymph nodes.</description>
        <time_frame>5 years</time_frame>
        <population>Post surgery population</population>
        <group_list>
          <group group_id="O1">
            <title>Chemoradiotherapy Plus Cetuximab</title>
            <description>Pelvic irradiation plus 5-fluorouracil plus cetuximab
Cetuximab
5-fluorouracil
Pelvic irradiation</description>
          </group>
          <group group_id="O2">
            <title>Chemoradiotherapy Alone</title>
            <description>Pelvic irradiation plus 5-fluorouracil
5-fluorouracil
Pelvic irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.</title>
          <description>A pathologic complete response (pCR) is defined as no pathologic evidence of invasive disease at the primary site in the bowel wall or in examined mesorectal tissue and/or lymph nodes.</description>
          <population>Post surgery population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="16.3" upper_limit="39.1"/>
                    <measurement group_id="O2" value="26.7" lower_limit="16.1" upper_limit="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine Objective Response Rate (ORR) Based on RECIST Local Recurrence-free Survival in These Patient Groups; Overall and Recurrence-free Survival in These Cohorts.</title>
        <description>Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.</description>
        <time_frame>5 years</time_frame>
        <population>Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Chemoradiotherapy Plus Cetuximab</title>
            <description>Pelvic irradiation plus 5-fluorouracil plus cetuximab
Cetuximab
5-fluorouracil
Pelvic irradiation</description>
          </group>
          <group group_id="O2">
            <title>Chemoradiotherapy Alone</title>
            <description>Pelvic irradiation plus 5-fluorouracil
5-fluorouracil
Pelvic irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine Objective Response Rate (ORR) Based on RECIST Local Recurrence-free Survival in These Patient Groups; Overall and Recurrence-free Survival in These Cohorts.</title>
          <description>Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.</description>
          <population>Evaluable Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" lower_limit="39.7" upper_limit="64.6"/>
                    <measurement group_id="O2" value="43.5" lower_limit="31.0" upper_limit="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5- Year Overall Survival (OS) Rate</title>
        <description>Overall survival is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the date of last contact.</description>
        <time_frame>5 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Chemoradiotherapy Plus Cetuximab</title>
            <description>Pelvic irradiation plus 5-fluorouracil plus cetuximab
Cetuximab
5-fluorouracil
Pelvic irradiation</description>
          </group>
          <group group_id="O2">
            <title>Chemoradiotherapy Alone</title>
            <description>Pelvic irradiation plus 5-fluorouracil
5-fluorouracil
Pelvic irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>5- Year Overall Survival (OS) Rate</title>
          <description>Overall survival is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the date of last contact.</description>
          <population>ITT population</population>
          <units>probability of overall survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.69" upper_limit="0.89"/>
                    <measurement group_id="O2" value="0.68" lower_limit="0.53" upper_limit="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence-free Survival (RFS) Rate at 5 Years</title>
        <description>RFS is measured from the date of randomization to the date of first documented disease recurrence or date of death, whichever comes first. If a patient neither recurrences nor dies, this patient will be censored at the date of last contact.</description>
        <time_frame>5 years</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Chemoradiotherapy Plus Cetuximab</title>
            <description>Pelvic irradiation plus 5-fluorouracil plus cetuximab
Cetuximab
5-fluorouracil
Pelvic irradiation</description>
          </group>
          <group group_id="O2">
            <title>Chemoradiotherapy Alone</title>
            <description>Pelvic irradiation plus 5-fluorouracil
5-fluorouracil
Pelvic irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence-free Survival (RFS) Rate at 5 Years</title>
          <description>RFS is measured from the date of randomization to the date of first documented disease recurrence or date of death, whichever comes first. If a patient neither recurrences nor dies, this patient will be censored at the date of last contact.</description>
          <population>ITT population</population>
          <units>probability of recurrence-free survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.51" upper_limit="0.76"/>
                    <measurement group_id="O2" value="0.585" lower_limit="0.44" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>KRAS Mutation Rate</title>
        <description>Percentage of Participants with KRAS mutation.</description>
        <time_frame>5 years</time_frame>
        <population>ITT population with KRAS test</population>
        <group_list>
          <group group_id="O1">
            <title>Chemoradiotherapy Plus Cetuximab</title>
            <description>Pelvic irradiation plus 5-fluorouracil plus cetuximab
Cetuximab
5-fluorouracil
Pelvic irradiation</description>
          </group>
          <group group_id="O2">
            <title>Chemoradiotherapy Alone</title>
            <description>Pelvic irradiation plus 5-fluorouracil
5-fluorouracil
Pelvic irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>KRAS Mutation Rate</title>
          <description>Percentage of Participants with KRAS mutation.</description>
          <population>ITT population with KRAS test</population>
          <units>percentage of participants with mutation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the whole treatment period, up to 30 days following last dose.</time_frame>
      <desc>For treatment patients only, assessed at each treatment visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Chemoradiotherapy Plus Cetuximab</title>
          <description>Pelvic irradiation plus 5-fluorouracil plus cetuximab
Cetuximab
5-fluorouracil
Pelvic irradiation</description>
        </group>
        <group group_id="E2">
          <title>Chemoradiotherapy Alone</title>
          <description>Pelvic irradiation plus 5-fluorouracil
5-fluorouracil
Pelvic irradiation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART, CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>VOLUME BLOOD DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>TACHYCARDIA ATRIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SWALLOWING PAINFUL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>WEAKNESS GENERALIZED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MUCOSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>COSTART, CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>LEUCOPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="67"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="67" subjects_affected="36" subjects_at_risk="67"/>
                <counts group_id="E2" events="60" subjects_affected="33" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="67"/>
                <counts group_id="E2" events="22" subjects_affected="13" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>WEAKNESS</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="67"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MUCOSAL SORES</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>MUCOSITIS</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="67"/>
                <counts group_id="E2" events="21" subjects_affected="12" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE WEAKNESS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>HAND-FOOT SYNDROME</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="99" subjects_affected="50" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David McCollum</name_or_title>
      <organization>US Oncology Network, McKesson Specialty Health</organization>
      <phone>214-370-1080</phone>
      <email>david.mccollum@usoncology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

